Ileana Bortolomai

Ileana Bortolomai

Auto-generated profile, based on publicly available information

Ileana Bortolomai

Telethon Institute for Gene Therapy (SR-Tiget), Division of Regenerative Medicine, Stem Cells, and Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SZSiming Zhao
Siming Zhao
MCMurim Choi
Murim Choi
JOJohn D. Overton
John D. Overton
SBStefania Bellone
Stefania Bellone
DRDana M. Roque
Dana M. Roque
ASAlessandro D. Santin
Alessandro D. Santin
Uterine serous carcinoma (USC) is a biologically aggressive subtype of endometrial cancer. We analyzed the mutational landscape of USC by whole-exome sequencing of 57 cancers, most of which were matched to normal DNA from the same patients. The distribution of the number of protein-altering somatic mutations revealed that 52 USC tumors had fewer than 100 (median 36), whereas 5 had more than 3,000 somatic mutations. The mutations in these latter tumors showed hallmarks of defects in DNA mismatch repair. Among the remainder, we found a significantly increased burden of mutation in 14 genes. In addition to well-known cancer genes (i.e., TP53 , PIK3CA , PPP2R1A , KRAS , FBXW7 ), there were frequent mutations in CHD4/Mi2b , a member of the NuRD–chromatin-remodeling complex, and TAF1 , an element of the core TFIID transcriptional machinery. Additionally, somatic copy-number variation was found to play an important role in USC, with 13 copy-number gains and 12 copy-number losses that occurred more often than expected by chance. In addition to loss of TP53 , we found frequent deletion of a small segment of chromosome 19 containing MBD3 , also a member of the NuRD–chromatin-modification complex, and frequent amplification of chromosome segments containing PIK3CA , ERBB2 (an upstream activator of PIK3CA), and CCNE1 (a target of FBXW7-mediated ubiquitination). These findings identify frequent mutation of DNA damage, chromatin remodeling, cell cycle, and cell proliferation pathways in USC and suggest potential targets for treatment of this lethal variant of endometrial cancer.

1 February 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SVstefano volpi
stefano volpi
YYYasuhiro Yamazaki
Yasuhiro Yamazaki
PBPatrick M. Brauer
Patrick M. Brauer
EREllen van Rooijen
Ellen van Rooijen
AHAtsuko Hayashida
Atsuko Hayashida
LNLuigi Daniele Notarangelo
Luigi Daniele Notarangelo
We studied three patients with severe skeletal dysplasia, T cell immunodeficiency, and developmental delay. Whole-exome sequencing revealed homozygous missense mutations affecting exostosin-like 3 (EXTL3), a glycosyltransferase involved in heparan sulfate (HS) biosynthesis. Patient-derived fibroblasts showed abnormal HS composition and altered fibroblast growth factor 2 signaling, which was rescued by overexpression of wild-type EXTL3 cDNA. Interleukin-2–mediated STAT5 phosphorylation in patients’ lymphocytes was markedly reduced. Interbreeding of the extl3-mutant zebrafish (box) with Tg(rag2:green fluorescent protein) transgenic zebrafish revealed defective thymopoiesis, which was rescued by injection of wild-type human EXTL3 RNA. Targeted differentiation of patient-derived induced pluripotent stem cells showed a reduced expansion of lymphohematopoietic progenitor cells and defects of thymic epithelial progenitor cell differentiation. These data identify EXTL3 mutations as a novel cause of severe immune deficiency with skeletal dysplasia and developmental delay and underline a crucial role of HS in thymopoiesis and skeletal and brain development.

15 March 2010 in Cell Cycle
Verified
Journal Article
Open access
PDF file
IBIleana Bortolomai
Ileana Bortolomai
SCSilvana Luciana Canevari
Silvana Luciana Canevari
IFIleana Facetti
Ileana Facetti
LCLoris De cecco
Loris De cecco
GCGiancarlo Castellano
Giancarlo Castellano
SMSilvia Miotti
Silvia Miotti
To investigate the tumor fraction with cancer stem/tumor initiating cell (CSC/TIC) characteristics, we tested the human cervical carcinoma cell lines A431, Caski and SiHa, by growth as non-adherent spheres in specific media and aldehyde dehydrogenase (ALDH) enzymatic activity. A good correlation between the two parameters was observed and the highest levels were observed in A431 cell line that was selected for characterization of the CSC/TIC fraction. A431 parental cells already displayed characteristics common to CSC/TIC, such as sphere forming efficiency, adherent holoclone formation and high ALDH activity. Non-adherent spheres maintained or increased these properties, and, in particular, ALDH-positive fraction increased from 46 to 65% and a transient induction of stem cell markers such as Nanog, Nestin and Oct4 was observed. Furthermore, a significant increase of paraclone forming cells was observed, suggesting that differentiation took place inside sphere cell populations. As compared to parental cells, spheres were characterized by: (1) a ten-fold higher verapamil-sensitive side population fraction; (2) the appearance of a podoplanin-positive subpopulation characterized by a small cell size; (3) the ability to propagate tumors in nude mice at a lower cell dose. The global gene expression analysis demonstrated a strong and reversible modulation of 'sphere' phenotype in comparison to parental and sphere cells re-induced to adherent conditions. All together our results indicated that the growth of A431 cells as a non-adherent sphere was not sufficient by itself to define a stem-like population, but it was essential for the emergence of a small population of tumor cells with CSC properties.


24 April 2012 in British Journal of Cancer
Verified
Journal Article
Open access
SBS Bellone
S Bellone
DRD Roque
D Roque
ECE Cocco
E Cocco
SGS Gasparrini
S Gasparrini
IBI Bortolomai
I Bortolomai
ASAlessandro Santin
Alessandro Santin
Background: Methods: Results: Conclusion:

2 June 2014 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
DEDiana P. English
Diana P. English
SBStefania Bellone
Stefania Bellone
CSCarlton L. Schwab
Carlton L. Schwab
IBIleana Bortolomai
Ileana Bortolomai
EBElena Bonazzoli
Elena Bonazzoli
ASAlessandro Santin
Alessandro Santin
Amplification of c‐erbB2 has been reported in over 30% of uterine serous carcinoma (USC) and found to confer poor survival because of high proliferation and increased resistance to therapy. In this study, we evaluated for the first time Trastuzumab emtansine (T‐DM1), a novel antibody–drug conjugate, against multiple epidermal growth factor receptor‐2 (HER2)‐positive USC cells in vitro followed by developing a supportive in vivo model. Fifteen primary USC cell lines were assessed by immunohistochemistry (IHC) and flow cytometry for HER2 protein expression. C‐erbB2 gene amplification was evaluated using fluorescent in situ hybridization. Sensitivity to T‐DM1 and trastuzumab (T)‐induced antibody‐dependent cell‐mediated cytotoxicity was evaluated in 5‐h chromium release assays. T‐DM1 and T cytostatic and apoptotic activities were evaluated using flow‐cytometry‐based proliferation assays. In vivo activity of T‐DM1 versus T in USC xenografts in SCID mice was also evaluated. High levels of HER2 protein overexpression and HER2 gene amplification were detected in 33% of USC cell lines. T‐DM1 was considerably more effective than trastuzumab in inhibiting cell proliferation and in causing apoptosis (P = 0.004) of USC showing HER2 overexpression. Importantly, T‐DM1 was highly active at reducing tumor formation in vivo in USC xenografts overexpressing HER2 (P = 0.04) and mice treated with TDM‐1 had significantly longer survival when compared to T‐treated mice and control mice (P ≤ 0.0001). T‐DM1 shows promising antitumor effect in HER2‐positive USC cell lines and USC xenografts and its activity is significantly higher when compared to T. T‐DM1 may represent a novel treatment option for HER2‐positive USC patients with disease refractory to trastuzumab and traditional chemotherapy.